^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

Published date:
07/28/2020
Excerpt:
In vitro experiments in ER+ breast cancer cells confirmed that FGFR/FGF alterations led to fulvestrant resistance as well as cross-resistance to the CDK4/6 inhibitor palbociclib.
DOI:
10.1158/1078-0432.CCR-19-3958